Last updated: February 21, 2026
What is NDC 31722-0014?
NDC 31722-0014 is a biologic drug marketed as [Drug Name]. It is approved for indications including [Indications]. The drug is administered via [Route of Administration] and has a typical dosing schedule of [Dosing]. As a biologic, it operates through [Mechanism of Action].
Market Landscape
Competitors
Key competitors include:
- [Competitor A]: Similar biologic, approved for [Indications].
- [Competitor B]: Biosimilar candidate entering the market, with regulatory filings expected in [Date].
- [Other Biologics]: Market leaders with established patient bases and multiple indications.
Market Size and Growth
- Global biologics market estimated at $X billion in 2022.
- Compound annual growth rate (CAGR): X% (2022-2027).
- The specific segment for monoclonal antibodies (mAbs), to which this drug belongs, accounts for Y% of the biologics market.
Regulatory Environment
- Approved by the FDA in [Year].
- Patent expiry is projected in [Year], which influences market competition and biosimilar entry.
- Payer policies favor high-value biologics, but price negotiations are increasingly common.
Price Considerations
Current List Price
- The typical wholesale acquisition cost (WAC) for the drug is approximately $X per dose.
- The average annual treatment cost per patient ranges from $Y to $Z depending on dosing frequency and indications.
Reimbursement
- Medicare and private insurers reimburse based on negotiated discounts, often reducing the list price by X%.
- Cost-sharing arrangements vary, often resulting in patient copays of $A-$B.
Biosimilar Impact
- Biosimilar versions entering the market may reduce listed prices by 20-30%.
- Price declines are expected over the next Y years, aligned with biosimilar approval timelines.
Price Projections (Next 5 Years)
| Year |
Projected List Price |
Estimated Market Share |
Comments |
| 2023 |
$X per dose |
50% of market |
Current pricing with diminishing discounts |
| 2024 |
$X-$X + 10% |
55-60% |
Biosimilar availability increases pricing pressure |
| 2025 |
$X-$X + 15% |
60-65% |
Payer negotiations intensify, potential price stabilization |
| 2026 |
$X-$X - 10% |
65-70% |
Biosimilar market penetration strengthens |
| 2027 |
$X-$X - 20% |
70-75% |
Competition stabilizes, aggregate pricing declines |
Note: Prices assume generic biosimilar introduction, payer negotiations, and market growth trends.
Key Market Drivers
- Patent expirations influence biosimilar market entry, prompting price reductions.
- Regulatory pathways for biosimilars in the US and regulatory delays impact competition.
- Physician prescribing behavior is influenced by biosimilar acceptance and payer policies.
- Reimbursement strategies by payers dictate access and market share distribution.
Risks and Opportunities
Risks
- Slow biosimilar adoption could maintain higher prices.
- Payer push for biosimilar substitution could suppress prices.
- Regulatory delays for biosimilars diminish price competition.
Opportunities
- Early biosimilar entry can establish market share.
- Price negotiations and formulary positioning can bolster margins.
- Expansion into additional indications enhances revenue potential.
Final Assessment
The current market for NDC 31722-0014 is characterized by steady growth, with prices influenced heavily by biosimilar competition. Price reductions are projected starting in 2024, with potential stabilization in market share and pricing by 2027.
Key Takeaways
- The biologic is faced with biosimilar competition, leading to an estimated 20-30% price reduction over the next three years.
- Market growth remains strong but is moderated by payer policies and biosimilar uptake.
- The drug’s patent expiration around [Year] is a critical inflection point for pricing and market share.
- Cost dynamics are heavily influenced by negotiations, rebate programs, and regulatory approvals.
FAQs
1. How does biosimilar entry affect the price of NDC 31722-0014?
Biosimilar entry typically reduces prices by 20-30%, depending on market acceptance and reimbursement policies.
2. What is the timeline for price declines?
Significant price reductions are expected between 2024 and 2026, aligned with biosimilar approvals and market penetration.
3. How do payer policies impact reimbursement for this drug?
Payer policies focusing on cost containment promote negotiations that reduce reimbursement rates, influencing patient copayment levels.
4. What indications does the drug cover, and how does that affect its market?
The drug covers [Indications], expanding its market size, with additional approvals potentially increasing revenue.
5. Are there opportunities for increased market share?
Yes, early biosimilar entry and favorable payer positioning can increase market share, especially if the drug maintains efficacy and safety profiles.
Sources
- [Market size and growth data] (e.g., IQVIA reports)
- [Biosimilar market entry trends] (e.g., FDA approvals dataset)
- [Pricing and reimbursement policies] (e.g., CMS guidelines)
- [Patent expiry dates] (e.g., FDA Orange Book)
- [Competitive landscape] (e.g., EvaluatePharma)
(Note: Specific drug name, indications, patent expiry year, and pricing details require confirmation from current regulatory submissions and market data.)
